AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01946373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Study NCT01946373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccine
Study NCT05476341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab injection
Description: Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
Study NCT05476341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab injection（Avastin）
Description: Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
Study NCT00944450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin phosphate anhydrous formulation
Description: Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.
Study NCT00944450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: sitagliptin phosphate monohydrate form
Description: Single dose sitagliptin 100 mg tablets \[monohydrate Final Market Image (FMI) form\] in one of two treatment periods.
Study NCT01467947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection
Description: Individual treatment duration per subject is 9 months, irrespective of the number of treated attacks. Each attack that occurs in this time frame will be treated with 20 IU Berinert/kg body weight.
Study NCT01718652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 300 mg capsule-shaped tablet taken orally (by mouth) on Days 1 through 8.
Study NCT01718652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Four 100 mg capsules (400 mg total dose) taken orally 30 minutes before the last dose of canagliflozin (JNJ-28431754) on Day 8.
Study NCT05546047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acthar Gel 80 UNT/ML Injectable Solution
Description: Follow up and observation for 12 months off Acthar gel or Acthar gel and Tacrolimus
Study NCT01136850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chloroquine, sulphadoxine pyrimethamine, LLIN
Description: > 50Kg: chloroquine base 150 mg 4 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~\< 50 Kg: chloroquine base 150 mg 3 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~Given at enrolment, 14-26 weeks gestation, by mouth.
Study NCT01136850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin, sulphadoxine pyrimethamine, LLIN
Description: sulphadoxine pyrimethamine (1500 mg/75 mg as single dose) plus azithromycin (1 g twice daily for 2 days).~Given three times by mouth at monthly intervals, commencing at between 14 and 26 weeks gestation.
Study NCT02474992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microclinic
Description: Individuals randomized to this arm will be invited to recruit members of their social network to form a health team, or microclinic. These groups will proceed through a discussion-based health education curriculum led by local community health workers. Topics will include HIV biology, medications, the importance of social support, and community outreach for reducing HIV stigma. The curriculum will conclude with an opportunity for all group members to disclose their HIV status to one another.
Study NCT04214912 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Personalized Survivor Care Plan (PSCP)
Description: Based the above literature review and our previous 10 years' efforts in OC patients' distress and care needs survey, we categorize OC patients' distress and needs into 6 major dimensions (1) symptoms management and dysfunction prevention (different kind of symptom, such as swallowing difficulty, eating difficulty, speaking difficulty, difficulty in opening mouth/trismus, shoulder dysfunction, mucositis, pain, fatigue, etc), (2) enhancing physical function (exercise skills, types for major parts of muscle training), (3) Confronting and dealing with psychological distress (fear, anxiety, depression, uncertainty), (4) nutrition assessment and counseling, (5) Social connection and RTW counseling (attitudes and skills for returning to work), and (6) overall needs assessment and supports.
Study NCT02827500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivabradine
Description: Active Comparator: ivabradine
Study NCT02827500 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Placebo Comparator: usual care
Study NCT01241760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
Study NCT01241760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: 1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
Study NCT01241760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
Study NCT01241760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: 750 mg (2 oral tablets) every 8 hours for 12 weeks
Study NCT00913614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplivanserin (SR46349)
Description: Oral administration
Study NCT01989702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fermented blueberry drink
Study NCT01989702 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Study NCT01989702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo drink
Study NCT01989702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sachets with probiotic bacterial powder
Study NCT01989702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sachets with placebo powder
Study NCT01989702 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sachets with placebo powder
Study NCT01846559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: E.coli Endotoxin Day 7 - 2 ng/kg
Study NCT01846559 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin
Description: E.coli Endotoxin Day 7 - 2 ng/kg
Study NCT01846559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily
Study NCT01846559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily
Study NCT04615325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7303359
Description: RO730359 will be administered as a single intravitreal injection.
Study NCT03112304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MATCH-ADTC
Description: MATCH - ADTC (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita \& Weisz, 2009) is a psychosocial intervention designed to treat children with multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. It is recommended for children aged 6-15. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
Study NCT03112304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRAC
Description: TRAC (Treatment Response Assessment for Children) is a web-based system that provides weekly monitoring of the MATCH modules used and the child's response to treatment. Child's response to treatment is based on caregiver and child reports of (a) changes in problem severity on the standardized Brief Problem Checklist, and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, TRAC provides a complete record of modules used, and child treatment response, across all the weeks of treatment, as illustrated in the client dashboard.
Study NCT03823950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: Begin G-CSF 72 hours following chemotherapy
Study NCT03177096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peds QL questionnaire and diabetes modulate
Description: Peds QL questionnaire and diabetes modulate is a pediatric questionnaire about quality of life - children's version and parents version : assessed in the 1st visit (enrollment visit) and after ten months ( V6 End of study)
Study NCT03177096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHO-5 questionnaire
Description: WHO-5 questionnaire is a questionnaire about quality of life : assessed in the 1st visit (enrollment visit) and after ten months (V6 End of Study) by the children
Study NCT03177096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Felt questionnaire
Description: Felt questionnaire completed by parents with regard to the welcome of their child in community and by the staffs in preschool, school or in out-of school center : assessed 2 months (V2) and ten months (V6 End of study) after enrollment visit
Study NCT03845972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SSFTB
Description: Patients who underwent major knee surgery and had already planned to perform subsartorial femoral triangle block (SSFTB) were included in the study. They were measured the outcomes the night before surgery. The saphenous nerve and nerve to vastus medialis were blocked at the subsartorial femoral triangle level by experienced anesthesiologists. After standard monitor, the distal femoral triangle was identified 2 cm proximal to the opening of adductor canal by ultrasound guidance. At this level, The location of nerve to vastus medialis was confirmed by nerve stimulator and it was blocked with 0.5% levobupivacaine 5 ml. Then, 0.5% levobupivacaine 10 ml would be injected perifemoral artery. The outcomes were re-assessed 30 min after block.
Study NCT01739803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Contract
Description: Intervention activities were performed by a study clinical pharmacist. Behavioral contract goal was achieving and maintaining IST adherence. Other components of the contract addressed: (a) motivation(s) or positive reinforcement for achieving IST adherence; (b) problems or barriers that may interfere with achieving IST adherence and possible solutions to overcome problems/barriers; (c) social support available to the RTR such as a significant other who may assist the RTR in following the IST dosing schedule; (d) tools/strategies the RTR may use to remind himself/herself to follow the IST dosing schedule; and (e) possible consequences of IST nonadherence (e.g., graft loss).
Study NCT01869413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours).
Study NCT01869413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
Study NCT01363583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoprostenol versus normal saline
Description: 0.5 ng/kilogram/minute during 4 days
Study NCT01363583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: epoprostenol versus normal saline
Description: 0.5 ng/kilogram/minute during 4 days
Study NCT01363583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 0.5-1.5 ml/hour during 4 days
Study NCT01529736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High torque insertion
Description: Osseotite implant placed with high insertion torque forces
Study NCT01529736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low torque insertion
Description: Osseotite implant placed with low insertion torque forces
Study NCT03101007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATTUNE Knee Prosthesis by DePuy
Description: Total Knee Replacement (TKR) Surgery with cementless ATTUNE rotating platform Knee Prosthesis by DePuy
Study NCT03101007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATTUNE Knee Prosthesis by DePuy
Description: Total Knee Replacement (TKR) Surgery with cementless ATTUNE rotating platform Knee Prosthesis by DePuy
Study NCT03101007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LCS Knee Prosthesis by DePuy
Description: Total Knee Replacement Surgery with cementless LCS rotating platform Knee Prosthesis by DePuy
Study NCT03101007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LCS Knee Prosthesis by DePuy
Description: Total Knee Replacement Surgery with cementless LCS rotating platform Knee Prosthesis by DePuy
Study NCT00413374 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Enoxaparin
Description: Patient takes 1.5 mg per kilogram, once daily, subcutaneous injections until INR is therapeutic, then medication is stopped.
Study NCT03443232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Description: Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice. According to the objective condition, the operator determine whether or not to carry out an additional cryoablation. Then we will applicate electrophysiological substrate mapping for guiding ablation of atrial fibrillation,If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
Study NCT03443232 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiofrequency ablation
Description: Each patient randomly allocated into the radiofrequency ablation group receives circumferential pulmonary vein isolation(CPVI),The default strategy is to create a circle surrounding the two ipsilateral pulmonary veins.We will mapping the left atrial subtrate. If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
Study NCT03426631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsule 30 minutes before sleep
Study NCT03426631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAW1033B2 oral capsule
Description: DAW1033B2 capsule 30 minutes before sleep
Study NCT00552448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Chest Compression VEST
Description: every 6 hours for 20 minutes
Study NCT01313819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj
Description: IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
Study NCT04117763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Empagliflozin once daily, for three months
Study NCT03851419 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of (Neuro)cysticercosis
Description: * Serological tests for cysticercosis~* Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis~* Stool testing for T. solium
Study NCT04403594 — intervention group
Intervention type: OTHER
Intervention: dry needling
Description: dry needling followed by functional electrical stimulation and treadmill training
Study NCT01694719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation Treatment for Depression
Study NCT01694719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Behavioral Activation Treatment for Depression
Study NCT01694719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Study NCT02578433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self Compassion
Description: Mindful Self Compassion (MSC) training has its primary focus on developing a friendly relationship with oneself by meditation,conversation with the group and the trainer, informal practice and homework assignments. These relationship is founded on mindfulness; therefore the participants will learn a way concentrate on the present moment. The orginal MSC training by Neff and Germer is well established, this intervention will be a shortened form of the original version and will last for the whole visit of the clinical patients in rehabilitation
Study NCT02578433 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Progressive Muscle Relaxation
Description: Progressive Muscle Relaxation by Jacobson is a well known relaxation technique where participants learn to recognize the difference between tension and relaxation by tensing and subsequently relaxing the muscles. The trainingw ill last the wohole stay and the control group will also do homework assignments.
Study NCT01771614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT01771614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperglycemia
Study NCT01965899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertable Cardiac Monitor Implant
Description: The Reveal LINQ is a leadless device that is recommended to be implanted in the region of the thorax. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG. The device stores ECG recordings from the patient-activated episodes and ECG recordings from automatically detected arrhythmias. Documentation of episode occurrence will be retained.
Study NCT03364413 — intervention group
Intervention type: OTHER
Intervention: Chocolate
Description: Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
Study NCT00721175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biliary stent (self expandable metallic stent)
Description: metallic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
Study NCT00721175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS
Description: plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
Study NCT01741337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation post-operative treatment for 6 months
Study NCT03691779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination tablet orally once daily in the morning.
Study NCT03691779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: IVA tablet orally once daily in the evening.
Study NCT02303821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study NCT02295033 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost irradiation
Study NCT03099447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocular electroacupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
Study NCT03099447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocular acupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
Study NCT03099447 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
Study NCT03879382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19/BCMA CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
Study NCT03879382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/d
Study NCT03879382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m2/d
Study NCT04052594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV